Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BIRT 2584 XX in Healthy Male Volunteers
NCT02256761Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2005
- Primary completion
- Jul 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BIRT 2584 XX in psoriasis and rheumatoid arthritis (RA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with abnormal findings in physical examination up to 45 days, Number of subjects with abnormal changes in laboratory parameters up to 45 days and 3 more. Started Jan 2005; status: completed.
02
Drugs
BIRT 2584 XX
03
Conditions
psoriasisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02256761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256761.